BACKGROUND: Pre-operative infection with organisms from the Burkholderia cepacia complex (BCC), particularly B cenocepacia, has been linked with a poorer prognosis after transplantation compared to patients with cystic fibrosis (CF) without this infection. Therefore, many transplant centers do not list these patients for transplantation. METHODS: We report the early and long-term results of a cohort of lung transplant recipients with CF and pre-operative BCC infection. Patients with pre-transplantation BCC infection were identified by case-note review. BCC species status was assigned by polymerase chain reaction (PCR)-based techniques. Survival rates were compared to recipients with CF without BCC infection. Survival rates in BCC subgroups were also compared, and then further analyzed pre- and post-2001, when a new immunosuppressive and antibiotic regime was introduced for such patients. RESULTS: Two hundred sixteen patients with CF underwent lung transplantation and 22 had confirmed pre-operative BCC infection, with 12 of these being B cenocepacia. Nine B cenocepacia-infected recipients died within the first year, and in 8 BCC sepsis was considered to be the cause of death. Despite instituting a tailored peri-operative immunosuppressive and microbiologic care approach for such patients, post-transplantation BCC septic deaths occurred frequently in those with pre-transplantation B cenocepacia infection. In contrast, recipients infected with other BCC species had significantly better outcomes, with post-transplantation survival comparable to other recipients with CF. CONCLUSIONS: Mortality in patients with B cenocepacia infection was unacceptably high and has led to our center no longer accepting patients with this condition onto the lung transplant waiting list. Long-term survival in the non-B cenocepacia BCC group was excellent, without high rates of acute rejection or bronchiolitis obliterans syndrome (BOS) longer term, and these patients continue to be considered for lung transplantation.
BACKGROUND: Pre-operative infection with organisms from the Burkholderia cepacia complex (BCC), particularly B cenocepacia, has been linked with a poorer prognosis after transplantation compared to patients with cystic fibrosis (CF) without this infection. Therefore, many transplant centers do not list these patients for transplantation. METHODS: We report the early and long-term results of a cohort of lung transplant recipients with CF and pre-operative BCC infection. Patients with pre-transplantation BCC infection were identified by case-note review. BCC species status was assigned by polymerase chain reaction (PCR)-based techniques. Survival rates were compared to recipients with CF without BCC infection. Survival rates in BCC subgroups were also compared, and then further analyzed pre- and post-2001, when a new immunosuppressive and antibiotic regime was introduced for such patients. RESULTS: Two hundred sixteen patients with CF underwent lung transplantation and 22 had confirmed pre-operative BCC infection, with 12 of these being B cenocepacia. Nine B cenocepacia-infected recipients died within the first year, and in 8 BCC sepsis was considered to be the cause of death. Despite instituting a tailored peri-operative immunosuppressive and microbiologic care approach for such patients, post-transplantation BCC septic deaths occurred frequently in those with pre-transplantation B cenocepacia infection. In contrast, recipients infected with other BCC species had significantly better outcomes, with post-transplantation survival comparable to other recipients with CF. CONCLUSIONS: Mortality in patients with B cenocepacia infection was unacceptably high and has led to our center no longer accepting patients with this condition onto the lung transplant waiting list. Long-term survival in the non-B cenocepacia BCC group was excellent, without high rates of acute rejection or bronchiolitis obliterans syndrome (BOS) longer term, and these patients continue to be considered for lung transplantation.
Authors: Benjamin T Kopp; Basant A Abdulrahman; Arwa A Khweek; Surender B Kumar; Anwari Akhter; Richard Montione; Mia F Tazi; Kyle Caution; Karen McCoy; Amal O Amer Journal: Biochem Biophys Res Commun Date: 2012-06-20 Impact factor: 3.575
Authors: Julia Klesney-Tait; Michael Eberlein; Lois Geist; John Keech; Joseph Zabner; Peter J Gruber; Mark D Iannettoni; Kalpaj Parekh Journal: Chest Date: 2015-05 Impact factor: 9.410
Authors: Marc Hartert; Omer Senbaklavacin; Bernhard Gohrbandt; Berthold M Fischer; Roland Buhl; Christian-Friedrich Vahld Journal: Dtsch Arztebl Int Date: 2014-02-14 Impact factor: 5.594
Authors: Kaivon Assani; Chandra L Shrestha; Frank Robledo-Avila; Murugesan V Rajaram; Santiago Partida-Sanchez; Larry S Schlesinger; Benjamin T Kopp Journal: J Immunol Date: 2017-01-16 Impact factor: 5.422
Authors: Bradley S Quon; Jenna Sykes; Sanja Stanojevic; Bruce C Marshall; Kristofer Petren; Josh Ostrenga; Aliza Fink; Alexander Elbert; Albert Faro; Christopher H Goss; Anne L Stephenson Journal: Clin Transplant Date: 2018-02-11 Impact factor: 2.863
Authors: Geert M Verleden; Lieven Dupont; Jonas Yserbyt; Veronique Schaevers; Dirk Van Raemdonck; Arne Neyrinck; Robin Vos Journal: J Thorac Dis Date: 2017-09 Impact factor: 2.895